Table 3.

Adult patient preference weights for SMA treatments from a conditional logit model with clustering

Attributes and levels	β coefficient	β coefficient 95% CI	Odds ratio	Odds ratio 95% CI
Motor function—reference category: stable
Improved by one level	0.851	0.557–1.145	2.342	1.746–3.144
Worse by one level	− 1.294	− 1.539 to − 1.050	0.274	0.215–0.350
Breathing function—reference category: stable
Improved	0.866	0.581–1.151	2.378	1.788–3.162
Worse	− 1.539	− 1.879 to − 1.200	0.215	0.153–0.301
Treatment administration—reference category: oral liquid taken once daily at home
Injection into the spine in hospital every 4 months	− 0.717	− 0.991 to − 0.443	0.488	0.371–0.642
Eyesight monitoring—reference category: no eye monitoring required
Monitoring during treatment if symptoms present	0.117	− 0.083 to 0.318	1.125	0.920–1.374
Monitoring twice a year for the first 2 years	0.204	− 0.023 to 0.430	1.226	0.977–1.538
Treatment reaction (fever, headache, vomiting and/or body pain)—reference category: no reaction
Reaction for 1–2 days every 4 months	0.018	− 0.219 to 0.254	1.018	0.803–1.289
Reaction for 3–4 days every 4 months	0.259	− 0.070 to 0.588	1.296	0.932–1.801
Contraception
Must use effective contraception	− 0.063	− 0.312 to 0.187	0.939	0.732–1.205

Figures in bold represent coefficients significant at P < 0.05

Model statistics: Wald Chi² (10) = 235.37; probability > Chi² = < 0.00; pseudo R² = 0.38

CI confidence interval, SMA spinal muscular atrophy